Sun Pharmaceutical Industries Ltd.
Formulation
API
Sun Pharmaceutical Industries Ltd. - Investor
Sun Pharmaceutical Industries Ltd. - Investor
Investor News
INVESTOR
SEARCH
Go
Annual Reports
Home >> Investor >> Annual Reports >> Annual Report 2005-06
API
Alendronate Sodium Escitalopram HBr Meloxicam Pamidronate Disodium
Amifostine trihydrate Esomeprazole Magnesium Mesalazine (5 ASA) Paroxetine HCL
Budesonide Flurbiprofen Metamizol Magnesium Pentoxifylline
Bupropion HCL R(-) Flurbiprofen Metformin HCl Pioglitazone
Carbamazepine S(-) Flurbiprofen Methylphenidate HCl Piroxicam Betacyclodextrin
Carboplatin Flurbiprofen Sodium Metoprolol Succinate Riluzole
Carvedilol Fluticasone Propionate Metoprolol Tartrate Rivastigmine Tartrate
Cisplatin Fluvoxamine Maleate Mirtazapine Ropinirole
Citalopram Hydrobromide Gabapentine Modafinil Sertraline HCL
Clomipramine HCl Glimepride Mometasone Furoate Sodium Valproate
Clonazepam Isradipine Naltrexone HCL Sumatriptan Succinate
Desloratidine Lercanidipine HCL Octreotide Tizanidine HCl
Desmopressin Monoacetate Letrozole Olanzapine Topiramate
Divalproex Sodium Losartan Potassium Ondansetron Base Tramadol HCl
Dobutamine HCl Loteprednol Etabonate Ondansetron HCl Dihydrate Valproic Acid
Dothiepin HCl Magnesium Valproate Oxaliplatin Venlafaxine HCL
Eptifibatide Oxcarbazepine Zolpidem Hemitartrate
Oxethazine Ziprasidone HCL
All transactions are carried out in conformity with patent laws applicable in the user country. Responsibility with respect to third party’s patent rights in a specific country lies exclusively with the buyer.
Prev 21 22 23 Next Top
SITE MAP   DISCLAIMER   PRIVACY POLICY   INTRANET    FIELD FORCE